Indication
Gastric or Gastroesophageal Junction Adenocarcinoma
11 clinical trials
29 products
Product
irinotecanProduct
IBI343Clinical trial
A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-05-30
Product
paclitaxelProduct
XmAb®23104Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
YervoyProduct
XmAb20717Product
TucatinibClinical trial
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of Tucatinib (MK-7119) in China Participants With HER2+ Advanced Breast Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-28
Product
PT886Clinical trial
A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination With Either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab TWINPEAK StudyStatus: Recruiting, Estimated PCD: 2025-12-01
Product
GemcitabineProduct
KeytrudaProduct
LeucovorinProduct
CapecitabineProduct
PaclitaxelProduct
AbraxaneProduct
OxaliplatinProduct
FluorouracilClinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)Status: Completed, Estimated PCD: 2023-02-16
Product
PembrolizumabProduct
XmAb®22841Product
CadonilimabClinical trial
Phase II Clinical Study of Cadonilimab Combination With Chemotherapy With or Without the Anti-CD47 Antibody AK117 Neoadjuvant/Adjuvant Therapy for Resectable Gastric or Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-11-30
Product
5-FluorouracilProduct
AK117Product
DocetaxelClinical trial
Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel, Oxaliplatin, S-1 (DOS) Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient (pMMR) Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-04-30
Product
Durvalumab and TremelimumabClinical trial
Efficacy and Safety of Serplulimab, Lenvatinib, and Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After First-line Immunotherapy: a Prospective, Single-armed Clinical TrialStatus: Recruiting, Estimated PCD: 2024-11-01
Product
SerplulimabProduct
LenvatinibClinical trial
Neoadjuvant Toripalimab in the Treatment of Locally Advanced dMMR/MSI-H Gastric or Gastroesophageal Junction Adenocarcinoma：an Open-label, Single-arm，Multi-center，Phase II TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Product
PD-1 inhibitorClinical trial
A Phase II Clinical Study of Trastuzumab in Combination With Capecitabine and Cisplatin (XP) in Patients With Tissue HER2-negative But Serum HER2-positive Advanced Gastric Cancer: XP+SamfenetStatus: Recruiting, Estimated PCD: 2024-12-31